Determinants of anti-S immune response at 6 months after COVID-19 vaccination in a multicentric European cohort of healthcare workers - ORCHESTRA project.
COVID – 19
health care workers (HCW)
immune response
serology
vaccine
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
04
07
2022
accepted:
13
09
2022
entrez:
17
10
2022
pubmed:
18
10
2022
medline:
19
10
2022
Statut:
epublish
Résumé
The duration of immune response to COVID-19 vaccination is of major interest. Our aim was to analyze the determinants of anti-SARS-CoV-2 IgG titer at 6 months after 2-dose vaccination in an international cohort of vaccinated healthcare workers (HCWs). We analyzed data on levels of anti-SARS-CoV-2 Spike antibodies and sociodemographic and clinical characteristics of 6,327 vaccinated HCWs from 8 centers from Germany, Italy, Romania and Slovakia. Time between 1 A 6-month serological response was detected in 99.6% of HCWs. Female sex (RR 1.10, 95%CI 1.00-1.21), past infection (RR 2.26, 95%CI 1.73-2.95) and two vaccine doses (RR 1.50, 95%CI 1.22-1.84) predicted higher IgG titer, contrary to interval since last dose (RR for 10-day increase 0.94, 95%CI 0.91-0.97) and age (RR for 10-year increase 0.87, 95%CI 0.83-0.92). M-RNA-based vaccines (p<0.001) and heterologous vaccination (RR 2.46, 95%CI 1.87-3.24, one cohort) were associated with increased antibody levels. Female gender, young age, past infection, two vaccine doses, and m-RNA and heterologous vaccination predicted higher antibody level at 6 months. These results corroborate previous findings and offer valuable data for comparison with trends observed with longer follow-ups.
Sections du résumé
Background
The duration of immune response to COVID-19 vaccination is of major interest. Our aim was to analyze the determinants of anti-SARS-CoV-2 IgG titer at 6 months after 2-dose vaccination in an international cohort of vaccinated healthcare workers (HCWs).
Methods
We analyzed data on levels of anti-SARS-CoV-2 Spike antibodies and sociodemographic and clinical characteristics of 6,327 vaccinated HCWs from 8 centers from Germany, Italy, Romania and Slovakia. Time between 1
Results
A 6-month serological response was detected in 99.6% of HCWs. Female sex (RR 1.10, 95%CI 1.00-1.21), past infection (RR 2.26, 95%CI 1.73-2.95) and two vaccine doses (RR 1.50, 95%CI 1.22-1.84) predicted higher IgG titer, contrary to interval since last dose (RR for 10-day increase 0.94, 95%CI 0.91-0.97) and age (RR for 10-year increase 0.87, 95%CI 0.83-0.92). M-RNA-based vaccines (p<0.001) and heterologous vaccination (RR 2.46, 95%CI 1.87-3.24, one cohort) were associated with increased antibody levels.
Conclusions
Female gender, young age, past infection, two vaccine doses, and m-RNA and heterologous vaccination predicted higher antibody level at 6 months. These results corroborate previous findings and offer valuable data for comparison with trends observed with longer follow-ups.
Identifiants
pubmed: 36248889
doi: 10.3389/fimmu.2022.986085
pmc: PMC9559243
doi:
Substances chimiques
Antibodies, Viral
0
COVID-19 Vaccines
0
Immunoglobulin G
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
986085Investigateurs
Carlotta Zunarelli
(C)
Roberta Bonfiglioli
(R)
Angela Carta
(A)
Giuseppe Verlato
(G)
Giuseppe Lippi
(G)
Davide Gibellini
(D)
Maria Diletta Pezzani
(MD)
Lorena Torroni
(L)
Michael Hoelscher
(M)
Andreas Wieser
(A)
Christina Reinkemeyer
(C)
Michael Plank
(M)
Ivan Noreña
(I)
Raquel Rubio-Acero
(R)
Simon Winter
(S)
Mihaela Leustean
(M)
Ovidiu Perseca
(O)
Madalina Ipate
(M)
Agripina Rascu
(A)
Jozef Strhársky
(J)
Petra Hellebrandt
(P)
Daniela Križanov Xe
(D)
Marianna Mrázov Xe
(M)
Luigi De Maria
(L)
Stefania Sponselli
(S)
Pasquale Stefanizzi
(P)
Antonio Caputi
(A)
Informations de copyright
Copyright © 2022 Collatuzzo, Visci, Violante, Porru, Spiteri, Monaco, Larese Fillon, Negro, Janke, Castelletti, De Palma, Sansone, Mates, Teodorescu, Fabiánová, Bérešová, Vimercati, Tafuri, Abedini, Ditano, Asafo, Boffetta and Orchestra WP5 Working Group.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Stat Med. 2002 Jun 15;21(11):1539-58
pubmed: 12111919
JAMA. 2021 Apr 13;325(14):1467-1469
pubmed: 33646292
Lancet Infect Dis. 2022 Jan;22(1):56-63
pubmed: 34509185
J Med Virol. 2022 Jan;94(1):279-286
pubmed: 34468990
Lancet. 2021 Sep 4;398(10303):856-869
pubmed: 34370971
Nat Rev Drug Discov. 2018 Apr;17(4):261-279
pubmed: 29326426
Curr Opin Physiol. 2018 Dec;6:16-20
pubmed: 30320243
Clin Chem Lab Med. 2021 Dec 16;60(3):456-463
pubmed: 34911170
Sci Rep. 2022 Feb 16;12(1):2628
pubmed: 35173254
Control Clin Trials. 1986 Sep;7(3):177-88
pubmed: 3802833
Lancet. 2021 Oct 16;398(10309):1407-1416
pubmed: 34619098
Vaccines (Basel). 2021 Oct 03;9(10):
pubmed: 34696233
Proc Natl Acad Sci U S A. 2018 Dec 4;115(49):12477-12482
pubmed: 30455317
Front Immunol. 2021 Apr 12;12:669339
pubmed: 33912196
Clin Microbiol Rev. 2019 Mar 13;32(2):
pubmed: 30867162
Lancet. 2022 Mar 5;399(10328):924-944
pubmed: 35202601
Front Immunol. 2022 Jan 03;12:775420
pubmed: 35046939
Vaccine. 2021 Nov 26;39(48):6984-6989
pubmed: 34763949
N Engl J Med. 2021 Apr 15;384(15):1412-1423
pubmed: 33626250
Curr Opin Virol. 2016 Apr;17:110-115
pubmed: 27031684
JAMA. 2021 Dec 28;326(24):2524-2526
pubmed: 34724529
Med Lav. 2022 Apr 26;113(2):e2022022
pubmed: 35481576
Front Immunol. 2021 Sep 27;12:728021
pubmed: 34646267
Nat Med. 2020 Nov;26(11):1691-1693
pubmed: 32929268
Nature. 2021 Aug;596(7870):109-113
pubmed: 34182569
J Clin Med. 2021 Aug 25;10(17):
pubmed: 34501264
N Engl J Med. 2021 Nov 18;385(21):2010-2012
pubmed: 34648703
N Engl J Med. 2021 Jun 10;384(23):2259-2261
pubmed: 33822494
J Infect Dis. 2014 Jul 15;209 Suppl 3:S114-9
pubmed: 24966191
Front Immunol. 2021 Dec 22;12:802858
pubmed: 35003131
Front Public Health. 2020 Jul 21;8:406
pubmed: 32793544
Emerg Microbes Infect. 2021 Dec;10(1):1751-1759
pubmed: 34396940
Med (N Y). 2022 Jan 14;3(1):25-27
pubmed: 35590141
BMJ. 2021 May 13;373:n1088
pubmed: 33985964
Nat Rev Immunol. 2008 Sep;8(9):737-44
pubmed: 18728636
Microorganisms. 2022 May 12;10(5):
pubmed: 35630462
Clin Microbiol Infect. 2022 Feb;28(2):202-221
pubmed: 34715347
Proc Natl Acad Sci U S A. 2020 Aug 18;117(33):20077-20087
pubmed: 32747563
Sci Rep. 2021 Mar 11;11(1):5788
pubmed: 33707646
Vaccine. 2022 Jan 28;40(4):650-655
pubmed: 34952755
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Lancet Respir Med. 2021 Sep;9(9):999-1009
pubmed: 34224675